Back

Plasma extracellular vesicle transcriptome as a dynamic liquid biopsy in acute heart failure

Gokulnath, P.; Spanos, M.; Lehmann, H. I.; Sheng, Q.; Rodosthenous, R.; Chaffin, M.; Varrias, D.; Chatterjee, E.; Hutchins, E.; Li, G.; Daaboul, G.; Rana, F.; Wang, A. M.; Keuren-Jensen, K. V.; Ellinor, P.; Shah, R.; Das, S.

2023-02-23 cardiovascular medicine
10.1101/2023.02.17.23285936
Show abstract

BackgroundAcute decompensation is associated with increased mortality in heart failure (HF) patients, though the underlying etiology remains unclear. Extracellular vesicles (EVs) and their cargo may mark specific cardiovascular physiologic states. We hypothesized that EV transcriptomic cargo, including long non-coding RNAs (lncRNAs) and mRNAs, is dynamic from the decompensated to recompensated HF state, reflecting molecular pathways relevant to adverse remodeling. MethodsWe examined differential RNA expression from circulating plasma extracellular RNA in acute HF patients at hospital admission and discharge alongside healthy controls. We leveraged different exRNA carrier isolation methods, publicly available tissue banks, and single nuclear deconvolution of human cardiac tissue to identify cell and compartment specificity of the topmost significantly differentially expressed targets. EV-derived transcript fragments were prioritized by fold change (-1.5 to + 1.5) and significance (<5% false discovery rate), and their expression in EVs was subsequently validated in 182 additional patients (24 control; 86 HFpEF; 72 HFrEF) by qRT-PCR. We finally examined the regulation of EV-derived lncRNA transcripts in human cardiac cellular stress models. ResultsWe identified 138 lncRNAs and 147 mRNAs (present mostly as fragments in EVs) differentially expressed between HF and control. Differentially expressed transcripts between HFrEF vs. control were primarily cardiomyocyte derived, while those between HFpEF vs. control originated from multiple organs and different (non-cardiomyocyte) cell types within the myocardium. We validated 5 lncRNAs and 6 mRNAs to differentiate between HF and control. Of those, 4 lncRNAs (AC092656.1, lnc-CALML5-7, LINC00989, RMRP) were altered by decongestion, with their levels independent of weight changes during hospitalization. Further, these 4 lncRNAs dynamically responded to stress in cardiomyocytes and pericytes in vitro, with a directionality mirroring the acute congested state. ConclusionCirculating EV transcriptome is significantly altered during acute HF, with distinct cell and organ specificity in HFpEF vs. HFrEF consistent with a multi-organ vs. cardiac origin, respectively. Plasma EV-derived lncRNA fragments were more dynamically regulated with acute HF therapy independent of weight change (relative to mRNAs). This dynamicity was further demonstrated with cellular stress in vitro. Prioritizing transcriptional changes in plasma circulating EVs with HF therapy may be a fruitful approach to HF subtype-specific mechanistic discovery. CLINICAL PERSPECTIVEO_ST_ABSWhat is new?C_ST_ABSWe performed extracellular transcriptomic analysis on the plasma of patients with acute decompensated heart failure (HFrEF and HFpEF) before and after decongestive efforts. Long non-coding RNAs (lncRNAs) within extracellular vesicles (EVs) changed dynamically upon decongestion in concordance with changes within human iPSC-derived cardiomyocytes under stress. In acute decompensated HFrEF, EV RNAs are mainly derived from cardiomyocytes, whereas in HFpEF, EV RNAs appear to have broader, non-cardiomyocyte origins. What are the clinical implications?Given their concordance between human expression profiles and dynamic in vitro responses, lncRNAs within EVs during acute HF may provide insight into potential therapeutic targets and mechanistically relevant pathways. These findings provide a "liquid biopsy" support for the burgeoning concept of HFpEF as a systemic disorder extending beyond the heart, as opposed to a more cardiac-focused physiology in HFrEF.

Matching journals

1
Circulation: Heart Failure
Ovid Technologies (Wolters Kluwer Health) · based on 11 published papers
#1
204× avg
2
Circulation
Ovid Technologies (Wolters Kluwer Health) · based on 37 published papers
Top 1%
33× avg
3
Circulation: Genomic and Precision Medicine
Ovid Technologies (Wolters Kluwer Health) · based on 30 published papers
Top 0.7%
40× avg
4
Nature Communications
Springer Science and Business Media LLC · based on 483 published papers
Top 9%
3.3× avg
5
Frontiers in Cardiovascular Medicine
Frontiers Media SA · based on 33 published papers
Top 2%
16× avg
6
Scientific Reports
Springer Science and Business Media LLC · based on 701 published papers
Top 37%
4.9%
7
Nature Genetics
Springer Science and Business Media LLC · based on 72 published papers
Top 3%
9.8× avg
8
Journal of the American Heart Association
Ovid Technologies (Wolters Kluwer Health) · based on 92 published papers
Top 7%
3.6× avg
9
European Heart Journal - Digital Health
Oxford University Press (OUP) · based on 15 published papers
Top 1.0%
19× avg
10
eLife
eLife Sciences Publications, Ltd · based on 262 published papers
Top 14%
2.2× avg
11
EMBO Molecular Medicine
Springer Science and Business Media LLC · based on 15 published papers
Top 0.4%
23× avg
12
Nature
Springer Science and Business Media LLC · based on 58 published papers
Top 5%
5.6× avg
13
European Heart Journal
Oxford University Press (OUP) · based on 14 published papers
Top 4%
9.2× avg
14
Journal of the American College of Cardiology
Elsevier BV · based on 11 published papers
Top 1%
19× avg
15
EBioMedicine
Elsevier BV · based on 21 published papers
Top 0.4%
15× avg
16
The American Journal of Cardiology
Elsevier BV · based on 15 published papers
Top 4%
7.8× avg
17
Hypertension
Ovid Technologies (Wolters Kluwer Health) · based on 20 published papers
Top 2%
8.1× avg
18
iScience
Elsevier BV · based on 74 published papers
Top 5%
5.3× avg
19
European Journal of Preventive Cardiology
Oxford University Press (OUP) · based on 12 published papers
Top 2%
19× avg
20
Arteriosclerosis, Thrombosis, and Vascular Biology
Ovid Technologies (Wolters Kluwer Health) · based on 11 published papers
Top 2%
13× avg
21
PLOS ONE
Public Library of Science (PLoS) · based on 1737 published papers
Top 93%
1.2%
22
Genome Medicine
Springer Science and Business Media LLC · based on 56 published papers
Top 7%
2.4× avg
23
eBioMedicine
Elsevier BV · based on 82 published papers
Top 7%
3.2× avg
24
Nature Medicine
Springer Science and Business Media LLC · based on 88 published papers
Top 17%
1.6× avg
25
BMC Cardiovascular Disorders
Springer Science and Business Media LLC · based on 11 published papers
Top 4%
7.8× avg
26
Cell Genomics
Elsevier BV · based on 34 published papers
Top 4%
6.8× avg
27
Biomedicines
MDPI AG · based on 21 published papers
Top 4%
5.2× avg